Japan PPI inflation slips to 11-mth low in July
Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc. (NASDAQ:CORT), recently conducted a significant stock transaction, selling shares valued at approximately $1.1 million. The sale comes as CORT shares have delivered an impressive 141% return over the past year, despite an 11.7% decline in the past week. This transaction was executed under a pre-established 10b5-1 trading plan on March 3, 2025, with the shares sold at an average price of $60.69.
In addition to the sale, Maduck also acquired shares through multiple transactions. He purchased shares worth approximately $15,712, with prices ranging from $0.00 to $59.07. Furthermore, he exercised stock options to acquire shares at a total value of $92,430, with an exercise price of $5.05 per share. The company, currently valued at $6.2 billion, maintains strong financial health with a current ratio of 3.35x and minimal debt.
Following these transactions, Maduck’s direct ownership stands at 85,622 shares, excluding any indirect holdings through entities such as Duckhill Capital, LLC and the Sean and Molly Maduck Living Trust. According to InvestingPro analysis, CORT appears fairly valued, with 13 additional exclusive ProTips available to subscribers, including detailed insights on the company’s valuation multiples and growth prospects.
In other recent news, Corcept Therapeutics reported its fourth-quarter 2024 earnings, revealing a shortfall in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS was $0.26, missing the expected $0.38, while revenue came in at $181.89 million, below the anticipated $198.05 million. Despite these misses, Corcept experienced a 40% year-over-year increase in annual revenue, reaching $675 million, with net income rising by 33% to $141 million. Additionally, the company has set a revenue guidance of $900 to $950 million for 2025, indicating confidence in continued growth.
In other developments, the U.S. Food and Drug Administration (FDA) accepted Corcept’s New Drug Application (NDA) for relacorilant, a treatment for endogenous hypercortisolism, with a decision expected by December 30, 2025. The NDA is supported by positive results from several trials, including the pivotal GRACE trial. Furthermore, Corcept is expanding its research in oncology and other areas, with ongoing studies in prostate cancer and metabolic dysfunction associated steatohepatitis (MASH).
Corcept’s CEO, Joseph Belanoff, expressed optimism about relacorilant’s potential to become a new standard of care for Cushing’s syndrome. The company is also addressing operational challenges with pharmacy partners and remains engaged in patent disputes with competitors. Analyst firms have not reported any recent upgrades or downgrades for Corcept, but the company’s strategic focus and financial outlook suggest a commitment to innovation and market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.